Filtros de búsqueda

Lista de obras de A Blauvelt

11. Allergic and immunologic diseases of the skin

artículo científico publicado en 2003

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

artículo científico publicado en 2014

A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis

artículo científico publicado en 2016

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

scientific article published on 02 September 2020

A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution

artículo científico publicado en 2016

A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S)

scientific article published on 20 February 2020

A boxed warning for inadequate psoriasis treatment

artículo científico publicado en 2016

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

artículo científico publicado en 2019

A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames

artículo científico publicado en 2006

Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells.

artículo científico publicado en 2013

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

scientific article published on 04 July 2019

Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes".

artículo científico publicado en 2018

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study

artículo científico publicado en 2020

Biosimilars for Psoriasis: Worldwide Overview of Regulatory Guidelines, Uptake and Implications for Dermatology Clinical Practice

artículo científico publicado en 2017

Blocking MAPK Signaling Downregulates CCL21 in Lymphatic Endothelial Cells and Impairs Contact Hypersensitivity Responses ⬇️

artículo científico publicado el 19 de mayo de 2011

C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells

artículo científico publicado en 2007

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT).

artículo científico publicado en 2018

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2).

artículo científico publicado en 2018

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

artículo científico publicado en 2010

Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.

artículo científico publicado en 2002

Clinical meaningfulness of complete skin clearance in psoriasis.

artículo científico publicado en 2016

Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial

scientific article published on 01 February 2020

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

scientific article published on 16 October 2019

Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

artículo científico publicado en 2003

Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab

scientific article published on 01 December 2019

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab

scientific article published on 09 March 2020

Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis

artículo científico publicado en 2019

Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab

scientific article published on 08 November 2019

Conjunctivitis in dupilumab clinical trials

artículo científico publicado en 2019

Consensus guidelines for the management of plaque psoriasis.

artículo científico publicado en 2012

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

artículo científico publicado en 2020

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

artículo científico publicado en 2018

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review

artículo científico publicado en 2021

Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells

scientific article published on 01 April 2003

Defining drug-free remission of skin disease in patients with plaque psoriasis

scientific article published on 09 November 2019

Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction ⬇️

artículo científico publicado el 6 de mayo de 2013

Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry

artículo científico publicado en 2018

Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype.

artículo científico publicado en 2006

Do IL-17 Inhibitors Increase Risk of Respiratory Tract Infections?

artículo científico publicado en 2020

Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial

artículo científico publicado en 2018

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

scientific article published on 17 June 2020

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

artículo científico publicado en 2018

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

scientific article published on 30 July 2019

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).

artículo científico publicado en 2016

Efalizumab for severe atopic dermatitis: a pilot study in adults

artículo científico publicado en 2006

Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen

artículo científico publicado en 2007

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial

artículo científico publicado en 2013

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.

artículo científico publicado en 2017

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

scientific article published on 08 April 2020

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial

scientific article published on 06 November 2019

Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis.

artículo científico publicado en 2018

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial

artículo científico publicado en 2020

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

artículo científico publicado en 2017

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials

article

Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P).

artículo científico publicado en 2018

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

scientific article published on 01 September 2018

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

artículo científico publicado en 2015

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa

artículo científico

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).

artículo científico publicado en 2017

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis

scientific article published on 22 July 2018

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

artículo científico publicado en 2018

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial

artículo científico publicado en 2020

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

artículo científico publicado en 2019

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials

scientific article published on 01 June 2018

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

artículo científico publicado en 2019

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

artículo científico publicado en 2019

Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis

artículo científico publicado en 2015

Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease

artículo científico publicado en 2002

Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.

artículo científico publicado en 2012

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

artículo científico publicado en 2013

Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation

artículo científico publicado en 2009

Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial

scientific article published on 18 March 2019

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

artículo científico publicado en 2019

HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters

artículo científico publicado en 2004

Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus

artículo científico publicado en 2006

IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice

artículo científico publicado en 2010

IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans

artículo científico publicado en 2010

IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies

artículo científico publicado en 2015

IL-23–Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A ⬇️

artículo científico publicado el 20 de diciembre de 2010

IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis

artículo científico publicado en 2017

Implications for Biologic Therapy:Staphylococcus aureusDecolonization of Individuals With a History of Recurrent Skin and Soft-Tissue Infections ⬇️

artículo científico publicado el 1 de agosto de 2013

Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes

artículo científico publicado en 2020

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

artículo científico publicado en 2019

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

artículo científico

Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis

artículo científico publicado en 2010

Inflammatory skin disease in K5.hTGF-beta1 transgenic mice is not dependent on the IL-23/Th17 inflammatory pathway

artículo científico publicado en 2009

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis

artículo científico publicado en 2018

Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).

artículo científico publicado en 2017

Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis

artículo científico

Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Prolongs the Life Span of Primary Human Umbilical Vein Endothelial Cells ⬇️

artículo científico publicado el 1 de junio de 2003

Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus express CCL21 ⬇️

artículo científico publicado el 5 de diciembre de 2010

Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

scientific article published on 13 August 2019

Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells

artículo científico publicado en 2004

Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

artículo científico publicado en 2020

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years

scientific article published on 01 August 2018

Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial

artículo científico publicado en 2020

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

scientific article published on 18 July 2019

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.

artículo científico publicado en 2019

Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized Phase 3b clinical trial

artículo científico publicado en 2018

Lymphatic Dysfunction Impairs Antigen-Specific Immunization, but Augments Tissue Swelling Following Contact with Allergens ⬇️

artículo científico publicado el 10 de noviembre de 2011

Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation

artículo científico publicado en 2015

Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter

artículo científico publicado en 2004

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

scientific article published on 04 December 2019

Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study.

artículo científico publicado en 2004

Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines

artículo científico publicado en 2002

Montagna Symposium 2008: The Biologic Basis of Psoriasis

artículo científico publicado en 2009

Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation ⬇️

artículo científico publicado el 7 de agosto de 2010

Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes

artículo científico publicado en 2006

Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium

artículo científico publicado en 2013

Orf-induced immunobullous disease: A distinct autoimmune blistering disorder

artículo científico publicado en 2007

PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes.

artículo científico publicado en 2004

PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes

artículo científico publicado en 2004

Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab ⬇️

artículo científico publicado el 1 de mayo de 2011

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines

artículo científico publicado en 2007

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial

artículo científico publicado en 2020

Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy

artículo científico publicado en 2013

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

artículo científico publicado en 2016

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

artículo científico publicado en 2018

Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6.

artículo científico publicado en 2002

Predicting Clinical Responses to Ustekinumab: Progress Toward a Future of Personalized Medicine

artículo científico publicado en 2019

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

artículo científico publicado en 2004

Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact

scientific article published on 25 September 2020

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials

artículo científico publicado en 2017

Quantifying the harmful effect of psoriasis on health-related quality of life

artículo científico publicado en 2002

R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms

artículo científico publicado en 2003

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).

artículo científico

Rapid publication for selected JAAD articles

artículo científico publicado en 2004

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

artículo científico publicado en 2017

Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council

scientific article published on 16 August 2019

Response to critical appraisal of LIBERTY AD CHRONOS

artículo científico publicado en 2018

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

artículo científico publicado en 2017

Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials

artículo científico publicado en 2018

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302)

artículo científico publicado en 2018

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

artículo científico publicado en 2019

Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomised Controlled Trials.

artículo científico publicado en 2018

Safety of secukinumab in the treatment of psoriasis

artículo científico publicado en 2016

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials

artículo científico publicado en 2015

Secukinumab Lowers Expression of ACE2 in Affected Skin of Patients With Psoriasis

artículo científico publicado en 2020

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial

artículo científico publicado en 2016

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study

scientific article published on 06 August 2019

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

article

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

artículo científico publicado en 2015

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.

artículo científico publicado en 2016

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

artículo científico publicado en 2016

Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infection among Satowanese islanders

artículo científico publicado en 2009

Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV.

artículo científico publicado en 2008

Stromal-derived factor 1 expression in the human thymus

scientific article published on 01 March 2002

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

artículo científico publicado en 2022

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

artículo científico publicado en 2018

T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis

artículo científico publicado en 2008

Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis

artículo científico publicado en 2009

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

scientific article published on 01 December 2018

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study

scientific article published on 09 December 2011

The future of academic dermatology in the United States: report on the resident retreat for future physician-scientists, June 15-17, 2001.

artículo científico publicado en 2002

The role of Langerhans cells in the sexual transmission of HIV.

artículo científico publicado en 2005

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

artículo científico publicado en 2017

Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox

artículo científico publicado en 2003

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

artículo científico publicado en 2020

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

artículo científico publicado en 2016

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting

artículo científico publicado en 2013

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting

artículo científico publicado en 2014

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda